title: A "vicious cycle" of NK-cell immune evasion in acute myeloid leukemia mediated by RANKL?
abstract: Receptor activator of NFκB ligand (RANKL) is mainly known for its role in bone metabolism, constituting a target for therapeutic interventions. Increasing evidence suggests that RANKL is also involved in oncogenesis and tumor progression, including a prominent role in host-tumor interaction. Our data suggest that targeting RANKL may reinforce natural killer (NK) cell-mediated antitumor responses in patients affected by hematological malignancies.
authors.affiliation: Department of Hematology and Oncology; Eberhard Karls University; Tuebingen, Germany.
authors.forename: Benjamin Joachim
authors.initials: BJ
authors.lastname: Schmiedel
authors.forename: Ludger
authors.initials: L
authors.lastname: Grosse-Hovest
authors.forename: Helmut Rainer
authors.initials: HR
authors.lastname: Salih
keywords: NK cells; RANK; RANKL; leukemia